Revolution Medicines 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Kick off this next discussion with Revolution Medicines. With me today, I have Mark Goldsmith, CEO. Mark, welcome. Thanks for joining us.
Thanks for having me. Mark, RASONQUE is on the market now.
You reported earnings recently, and the product's off to a strong launch. As you're now 10 weeks into approval, what has surprised you most about the launch, if anything, and what does it tell you about who RASONQUE is reaching today?
Well, we expected a strong launch. I think the most satisfying part of it so far has been the reach in terms of prescribers. As we mentioned last week, some 2,700 individual prescribers in that first five-week period. That's a pretty strong number, and it says that physicians were ready for it, they were looking for it, relative to the number of prescribers from the expanded access program, it's a much larger group. So that, I think, is very satisfying for us. It says that we're off to a good start there. In terms of what sorts of patients, most of the patients on the drug at this point in time are previously treated, either second line or some fraction of them being third line. And there are some things around the edges, but most of the patients are, as we'd expect, the previously treated pancreatic cancer patients.
Okay. Any sense of how the real-world experience with RASONQUE compares to what you saw in the RASolute 302 study?
Of course, we don't have quantitative metrics. That sort of information we don't really collect. It's not a clinical trial. But anecdotally, our field force is in regular contact with physicians. They will certainly hear about anything significant, and the feedback we get from them quite consistently is that patients are having a good experience. We've done a lot of work to prepare prescribers. Every site, every new site gets a visit. They get materials, they get education of the entire care team, and we've tried to preempt issues that could come up if somebody's not familiar. Our general experience, this was true in the phase III trial and it was true in the phase I/II trial as well, is that once a physician treats one or two patients with RASONQUE, they become familiar with what to expect.
Many of them will get used to the idea of prophylaxing, particularly with regard to skin manifestations. That will tend to reduce it, either the incidence or the severity, and then what to do when something happens. It's just about education. I think our group has done a good job, and so far the feedback has been patients are very satisfied with what they're getting.
How are physicians using the flexibility of the label, especially the NCCN guideline listings, which go beyond these core second-line PDAC population?
Yeah, it's pretty early to tell at this point. I mean, we only have reported five weeks' worth of information, and we don't really get access to some of that. It's only what we're told about, since a prescription per se doesn't give the medical history of the patient. Generally speaking, I think again, we're talking about mostly previously treated metastatic pancreatic cancer, but we know that there are prescriptions for indications beyond that. We know certainly there are prescriptions for first-line patients. That's on label, so that's not really quite what you're asking. A small number. Most patients are previously treated at this point. I think that will probably grow, but I can't project exactly how that will grow. We're aware that patients with non-metastatic disease, with locally advanced disease, just by tradition, receive the same care as patients with metastatic disease.
That's just common in pancreatic cancer. The same chemotherapies are used. When the NCCN decided to include that in its guidelines, that is locally advanced pancreatic cancer to receive RASONQUE, that's tradition in the field, so we weren't too surprised at that. I can't really give you any idea what fraction of patients at this point, but I think we can assume that those will go in the same direction as metastatic pancreatic cancer patients. Then there is also prescription going for indications outside of pancreatic cancer. Lung cancer, non-small cell lung cancer, we know that there are patients who have received it. That is also in the NCCN guidelines. That's not based on the approval or the label. That's based on a New England Journal paper that we published just 10 weeks ago or so, that reported encouraging initial results from a single-arm trial.
We're also aware of indications that go beyond that as well.
How big of a driver do you expect the first-line label to become over time? What data do you have from the RAS and RAS in that particular setting that could help drive early use there?
Well, we're evaluating a variety of regimens in first line. The label itself is for monotherapy in first line, and it refers to for patients who are not candidates for multi-agent systemic chemotherapy, which is a fairly flexible definition, and the FDA clearly wanted doctors and their patients to make those decisions. So that can expand or contract. It's really up to doctors and patients to decide. My guess is that that will grow over time as doctors get used to using the drug, as patients report their outcomes to the medicine. My guess is that will grow. I don't think it will shrink, but it's very hard to project that today.
Yeah. As investors and analysts building their models, you made some comments around some unique market dynamics early in the launch in the third quarter. Just remind us how you think that could impact the growth trajectory as we look forward.
Yeah, if I may, let me go back though to the previous question, then we could turn to that, and just point out my comments were about monotherapy, RASONQUE. We've also evaluated RASONQUE in combination with chemotherapy, which is something that pancreatic cancer docs asked us for. They said, "We don't want to give up chemotherapy in first line." Not all doctors said that, but many did. "So we'd like to see how does this monotherapy targeted agent add to chemotherapy, or how does chemotherapy add to that?" And we reported a cohort of patients in first line who received RASONQUE combined with GNP, gemcitabine, nab-paclitaxel, one of the two common regimens. And in that single arm study, patients did quite well in first line. So I think we have both monotherapy and chemo combination, and over time, those data will continue to evolve.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
